21.04.2022 • News

Henkel Seals Russian Exit Plans

Henkel has now decided to pull out of Russia, due to the country’s invasion of Ukraine. The German consumer chemicals producer said, however, it would keep paying its 2,500 employees there until the exit is complete.

In a statement, CEO Carsten Knobel said the company is working with its teams in Russia to make the transition as smooth as possible. The Düsseldorf-based manufacturer of branded products for home and beauty care, along with adhesives, said Henkel “condemns the Russian war against Ukraine and the violence against innocent civilians.”

Knobel added that the company is providing “extensive support” to its employees and the people of Ukraine and neighboring countries by offering financial donations as well as food and material donations.

Early in the war, Henkel wound down all advertising and sponsorship activity in Russia but as April started was still hesitant to pull the plug. It said, however, it was monitoring the situation while complying with all Western sanctions.

Executives told the annual general meeting on Apr. 4 that Henkel did not expect to have to write down any Russian assets. There was a threat, however, that brand names and some of the company’s 11 production facilities in the country could be expropriated.

Author: Dede Williams, Freelance Journalist

CEO Carsten Knobel said the company is working with its teams in Russia to make...
CEO Carsten Knobel said the company is working with its teams in Russia to make the transition as smooth as possible. (c) Henkel

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.